Crescent Biopharma, Inc. (CBIO) 10-Year Financial Performance & Capital Metrics

CBIO • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutCrescent Biopharma, Inc., an oncology company, develops therapies for cancer patients. Its pipeline includes a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates to treat solid tumors. The company is headquartered in Waltham, Massachusetts.Show more

Revenue $0 -100.0%
EBITDA $0 +100.0%
Net Income -$71M -93.7%
EPS (Diluted) -0.59 -1.7%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -623.21% -586.9%
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 12 (bottom 12%)
✗Low quality earnings: Net income not backed by cash flow
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-100%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-40.84%

EPS CAGR

10Y-

5Y-

3Y-

TTM-204278.44%

ROCE

10Y Avg-70.06%

5Y Avg-96.15%

3Y Avg-128.44%

Latest-213.27%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.26B	9.38	67	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	692.99M	4.09	10.76	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	932.87M	2.35	-1.84	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	630.68M	8.04	-2.62			-117.82%	0.18
IMNMImmunome, Inc.	2.22B	20.14	-4.03	-35.5%	-23.01%	-84.4%	0.03
NKTRNektar Therapeutics	744.1M	36.58	-4.21	9.22%	-192.87%	-141.9%	1.69
IBRXImmunityBio, Inc.	2.78B	2.82	-4.55	22.71%	-422.28%
CRVSCorvus Pharmaceuticals, Inc.	485.43M	6.50	-6.37			-21.01%	0.03

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	20.07M	18.5K	0	0	0	10.16M	1.16M	75K	10K	0
Revenue Growth %	0.34%	-1%	-1%	-	-	-	-0.89%	-0.94%	-0.87%	-1%
Cost of Goods Sold+	0	0	263.54K	275.12K	899.3K	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	20.07M	0	-263.54K	-275.12K	-899.3K	10.16M	1.16M	75K	10K	0
Gross Margin %	1%	-	-	-	-	1%	1%	1%	1%	-
Gross Profit Growth %	0.34%	-1%	-	-0.04%	-2.27%	12.3%	-0.89%	-0.94%	-0.87%	-1%
Operating Expenses+	32.86M	31.93M	33.93M	51.51M	61.39M	61.67M	64.61M	47.48M	39.29M	68.76M
OpEx % of Revenue	1.64%	1726.05%	-	-	-	6.07%	55.71%	633.04%	3928.53%	-
Selling, General & Admin	7.81M	8.65M	9.83M	11.41M	14.36M	16.74M	17.12M	19.09M	19.21M	12.63M
SG&A % of Revenue	0.39%	467.58%	-	-	-	1.65%	14.76%	254.49%	1921.3%	-
Research & Development	25.05M	23.28M	24.1M	40.09M	47.03M	44.93M	47.49M	28.39M	20.07M	56.14M
R&D % of Revenue	1.25%	1258.48%	-	-	-	4.42%	40.95%	378.55%	2007.17%	-
Other Operating Expenses	0	0	0	0	0	0	0	443	637	0
Operating Income+	-12.78M	-31.91M	-33.93M	-51.51M	-61.39M	-51.51M	-63.45M	-47.4M	-39.28M	-68.76M
Operating Margin %	-0.64%	-1725.05%	-	-	-	-5.07%	-54.71%	-632.04%	-3927.53%	-
Operating Income Growth %	-0.15%	-1.5%	-0.06%	-0.52%	-0.19%	0.16%	-0.23%	0.25%	0.17%	-0.75%
EBITDA+	-12.59M	-31.72M	-33.67M	-51.23M	-60.49M	-51.24M	-63.18M	-47.2M	-39.12M	0
EBITDA Margin %	-0.63%	-1714.75%	-	-	-	-5.04%	-54.48%	-629.28%	-3912.2%	-
EBITDA Growth %	-0.15%	-1.52%	-0.06%	-0.52%	-0.18%	0.15%	-0.23%	0.25%	0.17%	1%
D&A (Non-Cash Add-back)	191.48K	190.54K	263.54K	275.12K	899.3K	270.75K	264.6K	207.15K	153.3K	68.76M
EBIT	-12.78M	-31.91M	-33.93M	-51.5M	-61.39M	-51.51M	-63.45M	-47.4M	-39.27M	-68.76M
Net Interest Income+	0	103.65K	0	0	3.5M	482.49K	19.77K	714.52K	2.38M	935.27K
Interest Income	0	103.65K	0	3.23M	3.5M	482.49K	19.77K	714.52K	2.38M	935.27K
Interest Expense	0	0	0	0	0	0	0	0	0	0
Other Income/Expense	15.33K	103.65K	651.21K	3.23M	3.5M	482.49K	19.77K	714.96K	2.38M	-2.7M
Pretax Income+	-12.77M	-31.81M	-33.28M	-48.27M	-57.89M	-51.03M	-63.43M	-46.69M	-36.9M	-71.47M
Pretax Margin %	-0.64%	-1719.45%	-	-	-	-5.02%	-54.69%	-622.51%	-3689.88%	-
Income Tax+	0	0	0	3.23M	-3.78M	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	0.93%	1%	1%	1%	1%	1%
Net Income+	-12.77M	-31.81M	-33.28M	-48.27M	-54.12M	-51.03M	-63.43M	-46.69M	-36.9M	-71.47M
Net Margin %	-0.64%	-1719.45%	-	-	-	-5.02%	-54.69%	-622.52%	-3689.94%	-
Net Income Growth %	-0.15%	-1.49%	-0.05%	-0.45%	-0.12%	0.06%	-0.24%	0.26%	0.21%	-0.94%
Net Income (Continuing)	-12.77M	-31.81M	-33.28M	-48.27M	-57.89M	-51.03M	-63.43M	-46.69M	-36.9M	-71.47M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.67	-1.50	-1.13	-1.18	-1.25	-1.12	-1.23	-0.89	-0.58	-0.59
EPS Growth %	-0.12%	-1.24%	0.25%	-0.04%	-0.06%	0.1%	-0.1%	0.28%	0.35%	-0.02%
EPS (Basic)	-0.67	-1.50	-1.13	-1.18	-1.25	-1.12	-1.23	-0.89	-0.58	-0.59
Diluted Shares Outstanding	19.01M	21.26M	29.4M	41.04M	43.25M	45.72M	51.45M	52.53M	63.34M	64.48M
Basic Shares Outstanding	19.01M	21.26M	29.4M	41.04M	43.25M	45.72M	51.45M	52.53M	63.34M	64.48M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	47.24M	40.52M	127.22M	212.27M	162.53M	138.27M	90.79M	50.71M	43.79M	34.8M
Cash & Short-Term Investments	46.8M	40.04M	123.92M	209.92M	158.2M	137.04M	90.25M	47.87M	41.79M	34.77M
Cash Only	46.8M	40.04M	123.92M	209.92M	158.2M	137.04M	90.25M	47.87M	41.79M	34.77M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	38.68K	268.66K	101.95K	413.12K	185.95K	2.15K	1.35K	144.02K	175.82K	0
Days Sales Outstanding	0.7	5.3K	-	-	-	0.08	0.42	700.88	6.42K	-
Inventory	393.42K	198.84K	0	-405	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	0	0	38K
Total Non-Current Assets+	1.22M	1.87M	1.36M	2.57M	5.44M	4.56M	3.56M	1.1M	1.53M	813K
Property, Plant & Equipment	521.38K	1.06M	1.11M	957.23K	3.83M	2.95M	1.95M	751.17K	767.83K	0
Fixed Asset Turnover	38.50x	0.02x	-	-	-	3.45x	0.60x	0.10x	0.01x	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	696.53K	811.85K	256.68K	1.61M	1.61M	1.61M	1.61M	344.71K	757.91K	813K
Total Assets+	48.46M	42.39M	128.58M	214.84M	167.97M	142.83M	94.35M	51.81M	45.32M	35.62M
Asset Turnover	0.41x	0.00x	-	-	-	0.07x	0.01x	0.00x	0.00x	-
Asset Growth %	-0.15%	-0.13%	2.03%	0.67%	-0.22%	-0.15%	-0.34%	-0.45%	-0.13%	-0.21%
Total Current Liabilities+	7.75M	6.33M	8.17M	8.76M	10.95M	12.43M	11.82M	8.88M	6.84M	9.61M
Accounts Payable	564.24K	1.57M	2.65M	2.66M	1.44M	2.09M	2.11M	970.19K	868.12K	107K
Days Payables Outstanding	-	-	3.67K	3.53K	582.69	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	68.55K	0	0	0	0	0	0	0	0
Other Current Liabilities	0	68.55K	78.03K	98.77K	3.03M	3.91M	2.5M	2.97M	2.96M	76K
Current Ratio	6.10x	6.40x	15.56x	24.22x	14.84x	11.13x	7.68x	5.71x	6.41x	3.62x
Quick Ratio	6.05x	6.37x	15.56x	24.22x	14.84x	11.13x	7.68x	5.71x	6.41x	3.62x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	243.65K	753.58K	707K	611.62K	2.82M	2.18M	918.61K	0	66.84K	41.48M
Long-Term Debt	0	0	0	0	0	0	0	0	0	37.48M
Capital Lease Obligations	0	0	0	0	2.82M	1.92M	918.61K	0	66.84K	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	243.65K	753.58K	707K	611.62K	0	264.33K	0	0	0	4M
Total Liabilities	7.99M	7.09M	8.88M	9.38M	13.77M	14.61M	12.74M	8.88M	6.9M	51.1M
Total Debt+	0	0	0	0	3.62M	2.82M	1.92M	918.55K	808.4K	37.48M
Net Debt	-46.8M	-40.04M	-123.92M	-209.92M	-154.58M	-134.22M	-88.33M	-46.95M	-40.98M	2.72M
Debt / Equity	-	-	-	-	0.02x	0.02x	0.02x	0.02x	0.02x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-
Total Equity+	40.47M	35.3M	119.7M	205.46M	154.2M	128.22M	81.6M	42.93M	38.41M	-15.48M
Equity Growth %	-0.2%	-0.13%	2.39%	0.72%	-0.25%	-0.17%	-0.36%	-0.47%	-0.11%	-1.4%
Book Value per Share	2.13	1.66	4.07	5.01	3.56	2.80	1.59	0.82	0.61	-0.24
Total Shareholders' Equity	40.47M	35.3M	119.7M	205.46M	154.2M	128.22M	81.6M	42.93M	38.41M	-15.48M
Common Stock	19.05K	23.25K	34.36K	43.16K	43.47K	49.02K	52.31K	54.38K	64.39K	1K
Retained Earnings	-87.17M	-118.98M	-152.28M	-200.55M	-258.44M	-309.47M	-372.9M	-419.59M	-456.49M	-17.87M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-902.1K	-1.06M	-1.31M	-1.58M	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-8.24M	-29.73M	-29.77M	-43.33M	-51.98M	-39.24M	-57.49M	-46.46M	-34.88M	-31.1M
Operating CF Margin %	-0.41%	-1607.1%	-	-	-	-3.86%	-49.57%	-619.43%	-3487.99%	-
Operating CF Growth %	-0.92%	-2.61%	-0%	-0.46%	-0.2%	0.25%	-0.47%	0.19%	0.25%	0.11%
Net Income	-12.77M	-31.81M	-33.28M	-48.27M	-57.89M	-51.03M	-63.43M	-46.69M	-36.9M	-37.88M
Depreciation & Amortization	191.48K	190.54K	263.54K	275.12K	899.3K	270.75K	264.6K	207.15K	153.3K	35.17K
Stock-Based Compensation	2.32M	2.96M	3.76M	4.59M	0	6.9M	6.09M	3.86M	3.56M	0
Deferred Taxes	-2.32M	-2.96M	0	0	0	0	2.17K	0	0	0
Other Non-Cash Items	2.32M	2.96M	3.23M	168	6.22M	680.85K	749.04K	828.51K	864.87K	5.59M
Working Capital Changes	2M	-1.08M	-511.64K	80.11K	-1.21M	3.93M	-1.17M	-4.66M	-2.56M	1.16M
Change in Receivables	1.69M	0	0	0	0	0	0	0	0	0
Change in Inventory	474.44K	0	0	0	0	0	0	0	0	0
Change in Payables	-309.79K	1M	1.06M	16.49K	-1.23M	654.28K	17.68K	-1.14M	-102.08K	-538.81K
Cash from Investing+	-268.59K	-704.2K	-294.11K	-125.62K	-144.93K	-68.51K	-14.94K	-84.19K	-21.39K	20.03K
Capital Expenditures	-268.59K	-704.2K	-294.11K	-125.62K	-144.93K	-68.51K	-14.94K	-84.19K	-21.39K	-9.97K
CapEx % of Revenue	0.01%	38.06%	-	-	-	0.01%	0.01%	1.12%	2.14%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	-126K	0	0	0	0	0	0
Cash from Financing+	114.12K	23.67M	113.95M	129.45M	412.91K	18.14M	10.72M	4.16M	28.82M	5.4K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	114.12K	72.59K	373.38K	1.02M	0	319.3K	25.03K	0	116.5K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-8.51M	-30.44M	-30.06M	-43.46M	-52.13M	-39.31M	-57.5M	-46.54M	-34.9M	-31.11M
FCF Margin %	-0.42%	-1645.16%	-	-	-	-3.87%	-49.58%	-620.56%	-3490.13%	-
FCF Growth %	-0.89%	-2.58%	0.01%	-0.45%	-0.2%	0.25%	-0.46%	0.19%	0.25%	0.11%
FCF per Share	-0.45	-1.43	-1.02	-1.06	-1.21	-0.86	-1.12	-0.89	-0.55	-0.48
FCF Conversion (FCF/Net Income)	0.65x	0.93x	0.89x	0.90x	0.96x	0.77x	0.91x	1.00x	0.95x	0.44x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-27.98%	-83.96%	-42.94%	-29.69%	-30.09%	-36.14%	-60.46%	-74.98%	-90.72%	-623.21%
Gross Margin	100%	-	-	-	-	100%	100%	100%	100%	-
Net Margin	-63.62%	-171945.07%	-	-	-	-502.09%	-5468.98%	-62251.74%	-368994.2%	-
Debt / Equity	-	-	-	-	0.02x	0.02x	0.02x	0.02x	0.02x	-
FCF Conversion	0.65x	0.93x	0.89x	0.90x	0.96x	0.77x	0.91x	1.00x	0.95x	0.44x
Revenue Growth	33.56%	-99.91%	-100%	-	-	-	-88.59%	-93.53%	-86.67%	-100%

Revenue by Segment

	2024
Product	105.8M
Product Growth	-

Frequently Asked Questions

Growth & Financials

Crescent Biopharma, Inc. (CBIO) saw revenue decline by 100.0% over the past year.

Crescent Biopharma, Inc. (CBIO) reported a net loss of $56.0M for fiscal year 2024.

Dividend & Returns

Crescent Biopharma, Inc. (CBIO) has a return on equity (ROE) of -623.2%. Negative ROE indicates the company is unprofitable.

Crescent Biopharma, Inc. (CBIO) had negative free cash flow of $49.2M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Crescent Biopharma, Inc. (CBIO) 10-Year Financial Performance & Capital Metrics

CBIO • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

Revenue $0 -100.0%
EBITDA $0 +100.0%
Net Income -$71M -93.7%
EPS (Diluted) -0.59 -1.7%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -623.21% -586.9%
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 12 (bottom 12%)
✗Low quality earnings: Net income not backed by cash flow
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-100%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-40.84%

EPS CAGR

10Y-

5Y-

3Y-

TTM-204278.44%

ROCE

10Y Avg-70.06%

5Y Avg-96.15%

3Y Avg-128.44%

Latest-213.27%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.26B	9.38	67	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	692.99M	4.09	10.76	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	932.87M	2.35	-1.84	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	630.68M	8.04	-2.62			-117.82%	0.18
IMNMImmunome, Inc.	2.22B	20.14	-4.03	-35.5%	-23.01%	-84.4%	0.03
NKTRNektar Therapeutics	744.1M	36.58	-4.21	9.22%	-192.87%	-141.9%	1.69
IBRXImmunityBio, Inc.	2.78B	2.82	-4.55	22.71%	-422.28%
CRVSCorvus Pharmaceuticals, Inc.	485.43M	6.50	-6.37			-21.01%	0.03

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	20.07M	18.5K	0	0	0	10.16M	1.16M	75K	10K	0
Revenue Growth %	0.34%	-1%	-1%	-	-	-	-0.89%	-0.94%	-0.87%	-1%
Cost of Goods Sold+	0	0	263.54K	275.12K	899.3K	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	20.07M	0	-263.54K	-275.12K	-899.3K	10.16M	1.16M	75K	10K	0
Gross Margin %	1%	-	-	-	-	1%	1%	1%	1%	-
Gross Profit Growth %	0.34%	-1%	-	-0.04%	-2.27%	12.3%	-0.89%	-0.94%	-0.87%	-1%
Operating Expenses+	32.86M	31.93M	33.93M	51.51M	61.39M	61.67M	64.61M	47.48M	39.29M	68.76M
OpEx % of Revenue	1.64%	1726.05%	-	-	-	6.07%	55.71%	633.04%	3928.53%	-
Selling, General & Admin	7.81M	8.65M	9.83M	11.41M	14.36M	16.74M	17.12M	19.09M	19.21M	12.63M
SG&A % of Revenue	0.39%	467.58%	-	-	-	1.65%	14.76%	254.49%	1921.3%	-
Research & Development	25.05M	23.28M	24.1M	40.09M	47.03M	44.93M	47.49M	28.39M	20.07M	56.14M
R&D % of Revenue	1.25%	1258.48%	-	-	-	4.42%	40.95%	378.55%	2007.17%	-
Other Operating Expenses	0	0	0	0	0	0	0	443	637	0
Operating Income+	-12.78M	-31.91M	-33.93M	-51.51M	-61.39M	-51.51M	-63.45M	-47.4M	-39.28M	-68.76M
Operating Margin %	-0.64%	-1725.05%	-	-	-	-5.07%	-54.71%	-632.04%	-3927.53%	-
Operating Income Growth %	-0.15%	-1.5%	-0.06%	-0.52%	-0.19%	0.16%	-0.23%	0.25%	0.17%	-0.75%
EBITDA+	-12.59M	-31.72M	-33.67M	-51.23M	-60.49M	-51.24M	-63.18M	-47.2M	-39.12M	0
EBITDA Margin %	-0.63%	-1714.75%	-	-	-	-5.04%	-54.48%	-629.28%	-3912.2%	-
EBITDA Growth %	-0.15%	-1.52%	-0.06%	-0.52%	-0.18%	0.15%	-0.23%	0.25%	0.17%	1%
D&A (Non-Cash Add-back)	191.48K	190.54K	263.54K	275.12K	899.3K	270.75K	264.6K	207.15K	153.3K	68.76M
EBIT	-12.78M	-31.91M	-33.93M	-51.5M	-61.39M	-51.51M	-63.45M	-47.4M	-39.27M	-68.76M
Net Interest Income+	0	103.65K	0	0	3.5M	482.49K	19.77K	714.52K	2.38M	935.27K
Interest Income	0	103.65K	0	3.23M	3.5M	482.49K	19.77K	714.52K	2.38M	935.27K
Interest Expense	0	0	0	0	0	0	0	0	0	0
Other Income/Expense	15.33K	103.65K	651.21K	3.23M	3.5M	482.49K	19.77K	714.96K	2.38M	-2.7M
Pretax Income+	-12.77M	-31.81M	-33.28M	-48.27M	-57.89M	-51.03M	-63.43M	-46.69M	-36.9M	-71.47M
Pretax Margin %	-0.64%	-1719.45%	-	-	-	-5.02%	-54.69%	-622.51%	-3689.88%	-
Income Tax+	0	0	0	3.23M	-3.78M	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	0.93%	1%	1%	1%	1%	1%
Net Income+	-12.77M	-31.81M	-33.28M	-48.27M	-54.12M	-51.03M	-63.43M	-46.69M	-36.9M	-71.47M
Net Margin %	-0.64%	-1719.45%	-	-	-	-5.02%	-54.69%	-622.52%	-3689.94%	-
Net Income Growth %	-0.15%	-1.49%	-0.05%	-0.45%	-0.12%	0.06%	-0.24%	0.26%	0.21%	-0.94%
Net Income (Continuing)	-12.77M	-31.81M	-33.28M	-48.27M	-57.89M	-51.03M	-63.43M	-46.69M	-36.9M	-71.47M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.67	-1.50	-1.13	-1.18	-1.25	-1.12	-1.23	-0.89	-0.58	-0.59
EPS Growth %	-0.12%	-1.24%	0.25%	-0.04%	-0.06%	0.1%	-0.1%	0.28%	0.35%	-0.02%
EPS (Basic)	-0.67	-1.50	-1.13	-1.18	-1.25	-1.12	-1.23	-0.89	-0.58	-0.59
Diluted Shares Outstanding	19.01M	21.26M	29.4M	41.04M	43.25M	45.72M	51.45M	52.53M	63.34M	64.48M
Basic Shares Outstanding	19.01M	21.26M	29.4M	41.04M	43.25M	45.72M	51.45M	52.53M	63.34M	64.48M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	47.24M	40.52M	127.22M	212.27M	162.53M	138.27M	90.79M	50.71M	43.79M	34.8M
Cash & Short-Term Investments	46.8M	40.04M	123.92M	209.92M	158.2M	137.04M	90.25M	47.87M	41.79M	34.77M
Cash Only	46.8M	40.04M	123.92M	209.92M	158.2M	137.04M	90.25M	47.87M	41.79M	34.77M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	38.68K	268.66K	101.95K	413.12K	185.95K	2.15K	1.35K	144.02K	175.82K	0
Days Sales Outstanding	0.7	5.3K	-	-	-	0.08	0.42	700.88	6.42K	-
Inventory	393.42K	198.84K	0	-405	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	0	0	38K
Total Non-Current Assets+	1.22M	1.87M	1.36M	2.57M	5.44M	4.56M	3.56M	1.1M	1.53M	813K
Property, Plant & Equipment	521.38K	1.06M	1.11M	957.23K	3.83M	2.95M	1.95M	751.17K	767.83K	0
Fixed Asset Turnover	38.50x	0.02x	-	-	-	3.45x	0.60x	0.10x	0.01x	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	696.53K	811.85K	256.68K	1.61M	1.61M	1.61M	1.61M	344.71K	757.91K	813K
Total Assets+	48.46M	42.39M	128.58M	214.84M	167.97M	142.83M	94.35M	51.81M	45.32M	35.62M
Asset Turnover	0.41x	0.00x	-	-	-	0.07x	0.01x	0.00x	0.00x	-
Asset Growth %	-0.15%	-0.13%	2.03%	0.67%	-0.22%	-0.15%	-0.34%	-0.45%	-0.13%	-0.21%
Total Current Liabilities+	7.75M	6.33M	8.17M	8.76M	10.95M	12.43M	11.82M	8.88M	6.84M	9.61M
Accounts Payable	564.24K	1.57M	2.65M	2.66M	1.44M	2.09M	2.11M	970.19K	868.12K	107K
Days Payables Outstanding	-	-	3.67K	3.53K	582.69	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	68.55K	0	0	0	0	0	0	0	0
Other Current Liabilities	0	68.55K	78.03K	98.77K	3.03M	3.91M	2.5M	2.97M	2.96M	76K
Current Ratio	6.10x	6.40x	15.56x	24.22x	14.84x	11.13x	7.68x	5.71x	6.41x	3.62x
Quick Ratio	6.05x	6.37x	15.56x	24.22x	14.84x	11.13x	7.68x	5.71x	6.41x	3.62x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	243.65K	753.58K	707K	611.62K	2.82M	2.18M	918.61K	0	66.84K	41.48M
Long-Term Debt	0	0	0	0	0	0	0	0	0	37.48M
Capital Lease Obligations	0	0	0	0	2.82M	1.92M	918.61K	0	66.84K	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	243.65K	753.58K	707K	611.62K	0	264.33K	0	0	0	4M
Total Liabilities	7.99M	7.09M	8.88M	9.38M	13.77M	14.61M	12.74M	8.88M	6.9M	51.1M
Total Debt+	0	0	0	0	3.62M	2.82M	1.92M	918.55K	808.4K	37.48M
Net Debt	-46.8M	-40.04M	-123.92M	-209.92M	-154.58M	-134.22M	-88.33M	-46.95M	-40.98M	2.72M
Debt / Equity	-	-	-	-	0.02x	0.02x	0.02x	0.02x	0.02x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-
Total Equity+	40.47M	35.3M	119.7M	205.46M	154.2M	128.22M	81.6M	42.93M	38.41M	-15.48M
Equity Growth %	-0.2%	-0.13%	2.39%	0.72%	-0.25%	-0.17%	-0.36%	-0.47%	-0.11%	-1.4%
Book Value per Share	2.13	1.66	4.07	5.01	3.56	2.80	1.59	0.82	0.61	-0.24
Total Shareholders' Equity	40.47M	35.3M	119.7M	205.46M	154.2M	128.22M	81.6M	42.93M	38.41M	-15.48M
Common Stock	19.05K	23.25K	34.36K	43.16K	43.47K	49.02K	52.31K	54.38K	64.39K	1K
Retained Earnings	-87.17M	-118.98M	-152.28M	-200.55M	-258.44M	-309.47M	-372.9M	-419.59M	-456.49M	-17.87M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-902.1K	-1.06M	-1.31M	-1.58M	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-8.24M	-29.73M	-29.77M	-43.33M	-51.98M	-39.24M	-57.49M	-46.46M	-34.88M	-31.1M
Operating CF Margin %	-0.41%	-1607.1%	-	-	-	-3.86%	-49.57%	-619.43%	-3487.99%	-
Operating CF Growth %	-0.92%	-2.61%	-0%	-0.46%	-0.2%	0.25%	-0.47%	0.19%	0.25%	0.11%
Net Income	-12.77M	-31.81M	-33.28M	-48.27M	-57.89M	-51.03M	-63.43M	-46.69M	-36.9M	-37.88M
Depreciation & Amortization	191.48K	190.54K	263.54K	275.12K	899.3K	270.75K	264.6K	207.15K	153.3K	35.17K
Stock-Based Compensation	2.32M	2.96M	3.76M	4.59M	0	6.9M	6.09M	3.86M	3.56M	0
Deferred Taxes	-2.32M	-2.96M	0	0	0	0	2.17K	0	0	0
Other Non-Cash Items	2.32M	2.96M	3.23M	168	6.22M	680.85K	749.04K	828.51K	864.87K	5.59M
Working Capital Changes	2M	-1.08M	-511.64K	80.11K	-1.21M	3.93M	-1.17M	-4.66M	-2.56M	1.16M
Change in Receivables	1.69M	0	0	0	0	0	0	0	0	0
Change in Inventory	474.44K	0	0	0	0	0	0	0	0	0
Change in Payables	-309.79K	1M	1.06M	16.49K	-1.23M	654.28K	17.68K	-1.14M	-102.08K	-538.81K
Cash from Investing+	-268.59K	-704.2K	-294.11K	-125.62K	-144.93K	-68.51K	-14.94K	-84.19K	-21.39K	20.03K
Capital Expenditures	-268.59K	-704.2K	-294.11K	-125.62K	-144.93K	-68.51K	-14.94K	-84.19K	-21.39K	-9.97K
CapEx % of Revenue	0.01%	38.06%	-	-	-	0.01%	0.01%	1.12%	2.14%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	-126K	0	0	0	0	0	0
Cash from Financing+	114.12K	23.67M	113.95M	129.45M	412.91K	18.14M	10.72M	4.16M	28.82M	5.4K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	114.12K	72.59K	373.38K	1.02M	0	319.3K	25.03K	0	116.5K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-8.51M	-30.44M	-30.06M	-43.46M	-52.13M	-39.31M	-57.5M	-46.54M	-34.9M	-31.11M
FCF Margin %	-0.42%	-1645.16%	-	-	-	-3.87%	-49.58%	-620.56%	-3490.13%	-
FCF Growth %	-0.89%	-2.58%	0.01%	-0.45%	-0.2%	0.25%	-0.46%	0.19%	0.25%	0.11%
FCF per Share	-0.45	-1.43	-1.02	-1.06	-1.21	-0.86	-1.12	-0.89	-0.55	-0.48
FCF Conversion (FCF/Net Income)	0.65x	0.93x	0.89x	0.90x	0.96x	0.77x	0.91x	1.00x	0.95x	0.44x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-27.98%	-83.96%	-42.94%	-29.69%	-30.09%	-36.14%	-60.46%	-74.98%	-90.72%	-623.21%
Gross Margin	100%	-	-	-	-	100%	100%	100%	100%	-
Net Margin	-63.62%	-171945.07%	-	-	-	-502.09%	-5468.98%	-62251.74%	-368994.2%	-
Debt / Equity	-	-	-	-	0.02x	0.02x	0.02x	0.02x	0.02x	-
FCF Conversion	0.65x	0.93x	0.89x	0.90x	0.96x	0.77x	0.91x	1.00x	0.95x	0.44x
Revenue Growth	33.56%	-99.91%	-100%	-	-	-	-88.59%	-93.53%	-86.67%	-100%

Revenue by Segment

	2024
Product	105.8M
Product Growth	-

Frequently Asked Questions

Growth & Financials

Crescent Biopharma, Inc. (CBIO) saw revenue decline by 100.0% over the past year.

Crescent Biopharma, Inc. (CBIO) reported a net loss of $56.0M for fiscal year 2024.

Dividend & Returns

Crescent Biopharma, Inc. (CBIO) has a return on equity (ROE) of -623.2%. Negative ROE indicates the company is unprofitable.

Crescent Biopharma, Inc. (CBIO) had negative free cash flow of $49.2M in fiscal year 2024, likely due to heavy capital investments.